替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效及相关预测因子的Logistic回归分析

郭如意; 余雪平; 苏智军; 林成祖; 林志鹏; 林琪

替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效及相关预测因子的Logistic回归分析

福建医科大学附属泉州第一医院感染科

基金项目:

2008年泉州市科技计划项目(2008Z36)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3656
- HTML全文浏览量: 10
- PDF下载量: 809
- 被引次数: 0
出版历程
- 出版日期: 2013-02-20

Evaluation of telbivudine’s efficacy for treating HBeAg-positive chronic B hepatitis patients and identification of its predictive factors by logistic regression analysis

Research funding:

摘要

摘要:
目的观察替比夫定(LdT)治疗HBeAg阳性慢性乙型肝炎(CHB)患者3年的疗效,应用Logistic回归探讨HBeAg血清学转换的预测因子。方法收集58例采用LdT治疗的HBeAg阳性CHB患者,分析其性别、年龄、基线ALT水平、基线HBV DNA载量、基线HBeAg和HBsAg滴度与治疗3年时ALT复常率、HBV DNA阴转率、HBeAg阴转率和HBeAg血清转换率的相关性;采用Logistic回归分析HBeAg血清转换的相关因素。结果治疗3年时ALT复常率为84.48%,HBV DNA阴转率为70.69%,HBeAg阴转率为50.00%,HBeAg血清转换率为43.10%。与ALT≤2倍正常值上限(2×ULN)相比,基线ALT>5×ULN的患者HBeAg转换率显著增高(P<0.05);与hbeag≤100(s hbeag="">200 S/CO的患者HBeAg的阴转率和血清转换率均显著下降(P<0.05);与hbv 6="" hbv="" dna="">7 log拷贝/ml的患者HBV DNA转阴率、HBeAg转阴率和HBe...
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 替比夫定
Abstract:
Objective To evaluate the efficacy of a 36-month telbivudine (LdT) treatment regimen in patients with hepatitis B e antigen (HBeAg) -positive chronic hepatitis B (CHB) and to explore the predictive factors of LdT-induced HBeAg seroconversion using logistic regression analysis.Methods A total of 58 HBeAg-positive CHB patients treated with LdT continuously for 36 months were analyzed to determine any potential correlations between sex, age, baseline levels of alanine aminotransferase (ALT) , HBV DNA load, HBeAg titer, or hepatitis B surface antigen (HBsAg) titer and end-of-treatment rates of ALT normalization, undetectable HBV DNA, HBeAg clearance, or HBeAg seroconversion.The factors capable of predicting HBeAg seroconversion were identified by logistic regression analysis.Results After 36 months of LdT treatment, the ALT normalization rate was 84.48%, the undetectable HBV DNA rate was 70.69%, the HBeAg clearance rate was 50.0%, and the HBeAg seroconversion rate was 43.1%.The undetectable HBV DNA rate was significantly correlated to baseline HBV DNA load (P<0.05) .The HBeAg clearance rate was significantly correlated to baseline HBeAg titers and HBV DNA load (P<0.05) .The HBeAg seroconversion rate was significantly correlated to baseline ALT, HBeAg titers, and HBV DNA load (P<0.05) all="" of="" these="" indicators="" were="" unrelated="" to="" or="" baseline="" hbsag="" titers="" p="">0.05) .Multivariate logistic regression analysis showed that only the patients with lower baseline HBeAg titer were more likely to develop HBeAg seroconversion.Conclusion Continuous LdT treatment over 36 months can effectively improve liver function, suppress HBV replication, and increase the HBeAg seroconversion rate.Baseline HBeAg titer may be a useful predictive factor of the HBeAg seroconversion rate in HBeAg-positive CHB patients who are treated with LdT.
- hepatitis B /
- chronic /
- hepatitis B e antigen

HTML全文

参考文献(10)

[1] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association.The guidelineof prevention and treatment for chronic hepatitis B[J].JChin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.

[2]Tacke F, Trautwein C.Hepatitis B goes globe:Telbivudine asa new treatment option[J].Hepatology, 2008, 47 (5) :1786-1787.

[3]Jia JD, Hou JL, Yin YK, et al.The degree of HBV suppres-sion with 24 week telbivudine-or lamivudine-treatment inhepatitis B patients predicts the efficacy of the treatment atweek 52[J].Chin J Hepatol, 2007, 15 (5) :342-345. (inChinese) 贾继东, 侯金林, 尹有宽, 等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志, 2007, 15 (5) :342-345.

[4] Huang J, Chen XP, Chen XF, et al.Study on the efficacy andHBeAg seroconversion related factors of telbivudine and ente-cavir therapy in HBeAg positive chronic hepatitis B patients[J].Chin J Hepatol, 2011, 19 (3) :178-181. (in Chinese) 黄晶, 陈小苹, 陈学福, 等.慢性乙型肝炎的疗效及HBeAg血清学转换的预测因素[J].中华肝脏病杂志, 2011, 19 (3) :178-181.

[5]He CL.Evaluation of effectiveness of oral antiviral drugs for chron-ic hepatitis B[J].Chin Hepatol, 2008, 13 (2) :154-157. (in Chi-nese) 何长伦.慢性乙型肝炎的口服抗病毒药物评价[J].肝脏, 2008, 13 (2) :154-157.

[6]Chien RN, Liaw YF.Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan[J].Antivir Ther, 2006, 11 (7) :947-952.

[7]Wan MB.The expert panel symposinm on treatment for chronichepatitis B with lamivudine[J].Chin Hepatol, 2009, 14 (2) :167-169.

[8]Yao QJ, Ma WG.Therapeutic ef cacy of telbivudine in hepa-titis B e antigen positive chronic hepatitis B patients with highbaseline alanine aminotransferase levels[J].J Chin Hepatol, 2011, 27 (6) :614-616. (in Chinese) 姚钦江, 马卫国.替比夫定治疗高ALT水平HBeAg阳性慢性乙型肝炎的临床观察[J].临床肝胆病杂志, 2011, 27 (6) :614-616.

[9]Xu HX, Yu YX, Zhang MX, et al.Application of telbivudineand entecavir in the treatment of patients with HBeAg-posi-tive chronic hepatitis B[J].J Clin Hepatol, 2011, 14 (4) :265-267. (in Chinese) 徐鹤翔, 余亚新, 张明侠, 等.替比夫定和恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者早期疗效分析[J].实用肝脏病杂志, 2011, 14 (4) :265-267

[10]EASL Clinical Practice Guidelines:Management of Chronic Hep-atitis B[J].J Hepatol, 2009, 50 (2) :233-242.

施引文献

资源附件(0)

访问统计